Home › Funds › Parkman Healthcare Partners LLC › RCUS
Parkman Healthcare Partners LLC position in RCUS
ARCUS BIOSCIENCES INC · Health Care
Parkman Healthcare Partners LLC reported holding 675,516 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$17.4M, representing 1.57% of its reported portfolio and ranking #20 among its reported holdings. Parkman Healthcare Partners LLC has disclosed RCUS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's RCUS position evolved
Parkman Healthcare Partners LLC first disclosed a stake in RCUS in Q3 2023 at 205,109 shares (US$3.7M). The position peaked in Q2 2026 at 919,266 shares, worth US$28.3M. Across 13 filings, Parkman Healthcare Partners LLC increased the stake 8 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 675,516 shares valued at US$17.4M — a reduction of -243,750 shares quarter over quarter.. Notable position changes include a 60% increase in Q2 2024 (shares were roughly flat over the following quarter), a 147% increase in Q3 2024 (shares fell 3% over the following quarter), a 51% trim in Q2 2025 (shares rose 67% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 205.11K | $3.68M | New |
| Q4 2023 | 247.66K | $4.73M | Add |
| Q1 2024 | 259.92K | $4.91M | Add |
| Q2 2024 | 415.54K | $6.33M | Add |
| Q3 2024 | 1.03M | $15.68M | Add |
| Q4 2024 | 1.27M | $18.97M | Add |
| Q1 2025 | 1.22M | $9.54M | Reduce |
| Q2 2025 | 599.61K | $4.88M | Reduce |
| Q3 2025 | 652.68K | $8.88M | Add |
| Q4 2025 | 968.60K | $23.08M | Add |
| Q1 2026 | 1.21M | $26.08M | Add |
| Q2 2026 | 919.27K | $28.34M | Reduce |
| Q3 2026 | 675.52K | $17.45M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 43 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$811.7M), MONTANOVA CAPITAL, LLC (US$147.3M), Siren, L.L.C. (US$62.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- GILEAD SCIENCES, INC. 31.42M sh · $811.70M · Q3 2026
- MONTANOVA CAPITAL, LLC 4.78M sh · $147.26M · Q2 2026
- Siren, L.L.C. 2.42M sh · $62.52M · Q3 2026
- Soleus Capital Management, L.P. 1.17M sh · $36.03M · Q2 2026
- SAMLYN CAPITAL, LLC 1.39M sh · $36.03M · Q3 2026
- BAKER BROS. ADVISORS LP 844.82K sh · $26.05M · Q2 2026
- Sofinnova Investments, Inc. 626.18K sh · $16.17M · Q3 2026
- Ikarian Capital, LLC 504.56K sh · $15.56M · Q2 2026
- First Turn Management, LLC 577.69K sh · $14.92M · Q3 2026
- DAFNA Capital Management LLC 441.83K sh · $13.62M · Q2 2026
- Logos Global Management LP 500.00K sh · $12.91M · Q3 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held RCUS?
Parkman Healthcare Partners LLC has disclosed RCUS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Parkman Healthcare Partners LLC's current position in RCUS?
As of Q3 2026, Parkman Healthcare Partners LLC holds 675.52K shares of RCUS (ARCUS BIOSCIENCES INC), valued at $17.45M, representing 1.57% of its reported portfolio and ranking #20.
Has Parkman Healthcare Partners LLC been buying or selling RCUS?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC reduced its position in RCUS. The position peaked in Q2 2026 at 919.27K shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include GILEAD SCIENCES, INC., MONTANOVA CAPITAL, LLC, Siren, L.L.C., among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.